providers, governments and local communities to support and expand 
access to reliable, affordable health care around the world. For more 
than 150 years, we have worked to make a difference for all who rely on 
us. We routinely post information that may be important to investors on 
our website at 
https://www.globenewswire.com/Tracker?data=I_mUaTPBHrpldCVansihOHP8W3R7HaCM500LXtSgOWu3-zA36_ARhXnSOIucGKm7SKe93S2NK8uNygROHsY4xQ== 
www.Pfizer.com. In addition, to learn more, please visit us on 
https://www.globenewswire.com/Tracker?data=I_mUaTPBHrpldCVansihONxWLzSNtO-4Vqg4-uuLHzHO4YVtdfsNLZltKtvv_iDeFCBI87fD7xdeSBHoaDtX-w== 
www.Pfizer.com and follow us on Twitter at 
https://www.globenewswire.com/Tracker?data=dkHDOQ85a4aT4H_2oU-H40g11JotjeluPczctRwZWbWPz0lOH_8wM9Y4-vszc88Cv3WTMf5JL8jBwZwN3exQ_Q== 
@Pfizer and 
https://www.globenewswire.com/Tracker?data=dkHDOQ85a4aT4H_2oU-H454srP2XbNepFzPb45ezCUD3jfNjBjfF9rpsCFiVE_jXI3c17iujE3YfcLVGuVpr9S5bVVqAJoGUJJTrNnGrHI8= 
@Pfizer News, 
https://www.globenewswire.com/Tracker?data=FJ3DXw27Lb0watZsf3NeV0btzVBTWJ_Yg1ImUOfrzQnkpJo-rZR3rMHXCwR-pNJ8y_b_LE0vWvOLeQ2HU58NOFnl8XACUHw0BeiRNKE1fYc= 
LinkedIn, 
https://www.globenewswire.com/Tracker?data=jQieElnMsbJrtTfG6mOXL7G87VZMvtu0H8NLsi3UEE7pXdmCf21CFZ_58efWbUyRspf8yVN_r3KnSlePfbQ1IQ== 
YouTube and like us on Facebook at 
https://www.globenewswire.com/Tracker?data=vYxC9B2taAKW-GtMq2ImhYcprARh6T5aS2TacA5uu0EWLuEt3T43GYL7rfhHADLpvgQmEdR5yXrPvJvf4O38-D951jlcpsbsD_4SjkImyKc= 
Facebook.com/Pfizer. 
 
   Pfizer Disclosure Notice 
 
   The information contained in this release is as of February 18, 2021. 
Pfizer assumes no obligation to update forward-looking statements 
contained in this release as the result of new information or future 
events or developments. 
 
   This release contains forward-looking information about Pfizer's efforts 
to combat COVID-19, the collaboration between BioNTech and Pfizer to 
develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and the 
Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) (including qualitative 
assessments of available data, potential benefits, expectations for 
clinical trials, a Phase 2/3 clinical trial in pregnant women and 
planned trials in other populations, the anticipated timing of 
regulatory submissions, regulatory approval or authorization and 
anticipated manufacturing, distribution and supply) involving 
substantial risks and uncertainties that could cause actual results to 
differ materially from those expressed or implied by such statements. 
Risks and uncertainties include, among other things, the uncertainties 
inherent in research and development, including the ability to meet 
anticipated clinical endpoints, commencement and/or completion dates for 
clinical trials, regulatory submission dates, regulatory approval dates 
and/or launch dates, as well as risks associated with preclinical and 
clinical data (including the in vitro and Phase 3 data),  including the 
possibility of unfavorable new preclinical, clinical or safety data and 
further analyses of existing preclinical, clinical or safety data; the 
ability to produce comparable clinical or other results, including the 
rate of vaccine effectiveness and safety and tolerability profile 
observed to date, in additional analyses of the Phase 3 trial and 
additional studies or in larger, more diverse populations upon 
commercialization; the ability of BNT162b2 to prevent COVID-19 caused by 
emerging virus variants; the risk that more widespread use of the 
vaccine will lead to new information about efficacy, safety, or other 
developments, including the risk of additional adverse reactions, some 
of which may be serious; the risk that preclinical and clinical trial 
data are subject to differing interpretations and assessments, including 
during the peer review/publication process, in the scientific community 
generally, and by regulatory authorities; whether and when additional 
data from the BNT162 mRNA vaccine program will be published in 
scientific journal publications and, if so, when and with what 
modifications and interpretations; whether regulatory authorities will 
be satisfied with the design of and results from these and any future 
preclinical and clinical studies; whether and when a Biologics License 
Application for BNT162b2 may be filed in the U.S. and whether and when 
other biologics license and/or emergency use authorization applications 
may be filed in particular jurisdictions for BNT162b2 or any other 
potential vaccines, and if obtained, whether or when such emergency use 
authorization or licenses will expire or terminate; whether and when any 
applications that may be pending or filed for BNT162b2 (including a 
potential Biologics License Application in the U.S.) or other vaccines 
may be approved by particular regulatory authorities, which will depend 
on myriad factors, including making a determination as to whether the 
vaccine's benefits outweigh its known risks and determination of the 
vaccine's efficacy and, if approved, whether it will be commercially 
successful; decisions by regulatory authorities impacting labeling or 
marketing, manufacturing processes, safety and/or other matters that 
could affect the availability or commercial potential of a vaccine, 
including development of products or therapies by other companies; 
disruptions in the relationships between us and our collaboration 
partners or third-party suppliers; risks related to the availability of 
raw materials to manufacture a vaccine; challenges related to our 
vaccine's ultra-low temperature formulation and attendant storage, 
distribution and administration requirements, including risks related to 
storage and handling after delivery by Pfizer; the risk that we may not 
be able to successfully develop other vaccine formulations; the risk 
that we may not be able to create or scale up manufacturing capacity on 
a timely basis or maintain access to logistics or supply channels 
commensurate with global demand for our vaccine, which would negatively 
impact our ability to supply the estimated numbers of doses of our 
vaccine within the projected time periods as previously indicated; 
whether and when additional supply agreements will be reached; 
uncertainties regarding the ability to obtain recommendations from 
vaccine technical committees and other public health authorities and 
uncertainties regarding the commercial impact of any such 
recommendations; uncertainties regarding the impact of COVID-19 on 
Pfizer's business, operations and financial results; and competitive 
developments. 
 
   A further description of risks and uncertainties can be found in 
Pfizer's Annual Report on Form 10-K for the fiscal year ended December 
31, 2019 and in its subsequent reports on Form 10-Q, including in the 
sections thereof captioned "Risk Factors" and "Forward-Looking 
Information and Factors That May Affect Future Results", as well as in 
its subsequent reports on Form 8-K, all of which are filed with the U.S. 
Securities and Exchange Commission and available at www.sec.gov and 
www.pfizer.com. 
 
   About BioNTech 
 
   Biopharmaceutical New Technologies is a next generation immunotherapy 
company pioneering novel therapies for cancer and other serious 
diseases. The Company exploits a wide array of computational discovery 
and therapeutic drug platforms for the rapid development of novel 
biopharmaceuticals. Its broad portfolio of oncology product candidates 
includes individualized and off-the-shelf mRNA-based therapies, 
innovative chimeric antigen receptor T cells, bi-specific checkpoint 
immuno-modulators, targeted cancer antibodies and small molecules. Based 
on its deep expertise in mRNA vaccine development and in-house 
manufacturing capabilities, BioNTech and its collaborators are 
developing multiple mRNA vaccine candidates for a range of infectious 
diseases alongside its diverse oncology pipeline. BioNTech has 
established a broad set of relationships with multiple global 
pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal 
Health, Genentech, a member of the Roche Group, Regeneron, Genevant, 
Fosun Pharma, and Pfizer. For more information, please visit 
https://www.globenewswire.com/Tracker?data=I_mUaTPBHrpldCVansihOK1v3Lxr9s6WwluP8Vj9leRRbnvKdrMzEQaEX85Vl257xkBu5fYEePsuKodezaEvXg== 
www.BioNTech.de. 
 
   BioNTech Forward-looking Statements 
 
   This press release contains "forward-looking statements" of BioNTech 
within the meaning of the Private Securities Litigation Reform Act of 
1995. These forward-looking statements may include, but may not be 
limited to, statements concerning: BioNTech's efforts to combat 
COVID-19; the collaboration between BioNTech and Pfizer to develop a 
COVID-19 vaccine; our expectations regarding the characteristics of 
BNT162b2 in our Phase 2/3 trial and/or in commercial use based on data 
observations to date; the ability of BNT162b2 to prevent COVID-19 caused 
by emerging virus variants, the expected time point for additional 
readouts on efficacy data of BNT162b2 in our Phase 2/3 trial; the nature 
of the clinical data, which is subject to ongoing peer review, 
regulatory review and market interpretation; the timing for submission 
of data for, or receipt of, any marketing approval or Emergency Use 
Authorization; our contemplated shipping and storage plan, including our 
estimated product shelf life at various temperatures; and the ability of 
BioNTech to supply the quantities of BNT162 to support clinical 
development and market demand, including our production estimates for 
2021. Any forward-looking statements in this press release are based on 
BioNTech current expectations and beliefs of future events, and are 
subject to a number of risks and uncertainties that could cause actual 
results to differ materially and adversely from those set forth in or 
implied by such forward-looking statements. These risks and 
uncertainties include, but are not limited to: the ability to meet the 
pre-defined endpoints in clinical trials; competition to create a 
vaccine for COVID-19; the ability to produce comparable clinical or

(MORE TO FOLLOW) Dow Jones Newswires

February 18, 2021 13:30 ET (18:30 GMT)